Psoriatic Arthritis Treatment Market By Molecule Type (Monoclonal Antibodies, Fusion Proteins, Small Molecules, Biosimilars, Conventional Synthetic Drugs (csDMARDs)), By Mechanism of Action (TNF-α Inhibitors, IL-17 Inhibitors, IL-12/23 Inhibitor, IL-23 Inhibitors, JAK Inhibitors, PDE4 Inhibitor, Conventional DMARDs, NSAIDs & Corticosteroids), By Route of Administration (Subcutaneous (SC) Injection, Intravenous (IV) Infusion, Oral, Intra-articular), By Phenotype (Peripheral Arthritis-predominant, Axial PsA, Enthesitis-dominant, Dactylitis-dominant, Nail Disease Involvement, Psoriasis with Joint Involvement), By End-user (Hospitals & Hospital Pharmacies, Specialty Clinics, Ambulatory Infusion Centers, Self-administration Settings, Retail & Online Pharmacies, Other), Global Market Size, Segmental Analysis, Regional Overview, Company Share Analysis, Leading Company Profiles And Market Forecast, 2025–2035

---

What trends will shape the Psoriatic Arthritis Treatment Market in the coming years?

The Psoriatic Arthritis Treatment Market accounted for USD 11.58 Billion in 2024 and USD 12.73 Billion in 2025 is expected to reach USD 32.91 Billion by 2035, growing at a CAGR of around 9.96% between 2025 and 2035. The psoriatic arthritis treatment market is poised to change with a number of transformational trends in the near future. The growth in the uptake of biologics and targeted synthetic agents like JAK and IL-17/IL-23 inhibitors will continue to fuel the market. Biosimilars will likely increase access and decrease the cost of treating patients in the more price-sensitive markets. The developments of precision medicine and treat-to-target will enhance personalized therapy selection and management of the disease. The increasing interest in oral small molecules and user-friendly self-administered injectables will drive adherence in patients.

There is also an increasing interest in digital health technologies and remote monitoring, which allows integrating information on medical practice, in particular, real-world data, into treatment pathways. The footprint of psoriatic arthritis is on the increase due to the combination of the presented factors, namely, early diagnosis programs. The increased adoption of therapies will be driven by the expansion of patient-support programs and value-based reimbursement. In addition, a high number of new immunotherapies and TYK2 inhibitors are anticipated to transform the competitive arena significantly.

What do industry experts say about the Psoriatic Arthritis Treatment market trends?

“There are many psoriatic arthritis patients with poor response to existing treatments. The mode of action of Allocetra™ may become a new modality in treating these patients. We are pleased to announce the initiation of a new clinical program in psoriatic arthritis and are looking forward to commencing the study as a first step to our future development of a potentially effective treatment option for these patients.”

• Oren Hershkovitz, Ph.D., CEO of Enlivex.

Which segments and geographies does the report analyze?

What are the key drivers and challenges shaping the Psoriatic Arthritis Treatment market?

How is the rising global prevalence of psoriatic arthritis fueling treatment market expansion?

In the Global Psoriatic Arthritis Treatment Market, increasing global prevalence of psoriatic arthritis is a key driving factor, as it increases patient demand to access more advanced treatment options in the market. Latest reported government figures show that about 112 people per million of the world's adult population are affected by the condition, representing a huge burden to the health systems of the different governments. Such a swelling patient population is fueling demand for effective biologics, small molecules, and biosimilars to control the symptoms and inhibit joint destruction.

Increased prevalence is also compelling health care professionals to give importance to early diagnosis and intervention so that there will be early access to treatment. The responses of pharmaceutical companies are focused on faster research and clinical trials and products that respond to unmet patient needs. To a growing number of patients in emerging economies, the access and government support offered to healthcare are improving the options of modern therapies. In the meantime, advanced economies are concerned with the individualized care ambitions to improve patient outcomes. Increasing awareness campaigns and better screening habits are also leading to early detection of cases. Together, these things are reinforcing the treatment ecosystem as a whole. This has led to a stable growth in the market in terms of global demand.

Why does increasing adoption of biologics and targeted therapies boost therapeutic revenue growth worldwide?

The presence of an increasing use of biologics and targeted therapeutics is another significant medical component that is enhancing therapeutics growth in revenue worldwide, as these medications provide improved treatment efficacy in offering specific intervention of immune dynamics. TNF, IL-17, and IL-23 inhibitors are becoming more favored owing to the fact that they confer a better disease management experience, inflammation reduction, and patient quality of life than traditional pharmaceuticals. According to the government health data, one of the highest spending areas on anything pharmaceutical has now become the biologic and immunology drugs, as it is now under the scanner due to the wide use of drugs and their effect on treatment costs. Delivery of premium services coupled with the rising prescription denomination is fueling the growth of revenues across healthcare infrastructures worldwide.

The prescribing of these therapies is increasingly being adopted by physicians because there are changes in the clinical guidelines that incorporate the use of biologics as a first-line or second-line therapy. Patients also exhibit greater compliance in this case, as the biologics relieve pain faster and do not cause as many long-term complications. Pharma companies are setting up biologic pipelines to take advantage of the increased targeted therapy demands. Coupled with regulatory approvals that confirm the safety and efficacy of these therapies, regulatory approvals also support them. Further, specialty clinics and infusion centers are modifying the state of infrastructure to cope with the increasing administration of biologics. Altogether, the growing importance of biologics and targeted therapies is transforming revenue trends and ensuring their hegemony in psoriatic arthritis.

Why does high treatment cost restrict access to biologics among lower-income patients?

In the Global Psoriatic Arthritis Treatment Market, biologic therapy is associated with high costs, which reduces equality in treatment and the outcome of the treatment for lower-income patients. As highly targeted therapies, the prices of the biologics are significantly higher than conventional drugs, which poses financial barriers to access to the medication by the uninsured and underinsured groups. Co-payments and out-of-pocket expenses. The unknown notion began to bridge this gap with healthcare coverage, but even in the areas where it covers the costs, they are still overwhelming.

Access to therapy can be a problem, with low- and middle-income countries having a severe lack of reimbursement programs to fall back on, impeding the initiation or continuation of biologic treatment. Such high prices create a barrier to the use of more effective therapies, so disease progression is not effectively controlled in many cases. Restricted access also increases healthcare inequality, as the limited healthcare breakthroughs will be enjoyed by only the rich. The pharmaceutical companies use high R&D and manufacturing costs as excuses to justify the high prices charged for the biologics, compounding the difficulty of reducing costs. The affordability gap is improved by the delayed availability of biosimilars in various regions, making biologics unaffordable to most. This consequently leads to discontinuation of treatment amongst poor patients. On balance, the economic overhead of biologics is a major limiting factor in increasing equitable world access to advanced psoriatic arthritis treatment regimes.

How will biosimilar drug introductions expand affordability and market penetration in emerging countries?

Penetration of biosimilar drugs in the Global Psoriatic Arthritis Treatment Market continues to grow in importance due to their ability to lower costs for healthcare systems and patients in emerging markets. Biosimilars are estimated to lead to a reduction in costs by almost 60%, compared to the biologics they are analogous to, hence being an affordable alternative to resource-strapped communities. Such a price decrease strongly motivates governments and institutions to stock them in national formularies and reimbursement schemes, increasing treatment access. In some geographies, such as China, potential savings per patient exceed $874 to $2,184 per month, so thousands more patients can have access to therapy. These cost reductions not only make them practical to the people but also help the healthcare systems to utilize their resources better.

The reduced cost of biosimilars enhances the confidence of the patient and the adherence levels since more people who are in need of treatment can now afford biosimilars and access treatment. Besides, it helps health professionals to provide biologics-based medical services to more and hitherto underserved people. A broader usage of biosimilars also fosters the presence of competition in the market, provoking a decline in prices of therapeutic classes in general. The trend aids in enhancing better healthcare equity through minimized disparities between high-income and low-income groups. The long-term impacts of increased accessibility of biosimilars in the Global Psoriatic Arthritis Treatment Market include sustainable growth, positive patient outcomes, and the long-term expansion of treatment options across the industry.

Why does an advancing precision medicine approach open avenues for highly personalized arthritis treatment strategies?

The Global Psoriatic Arthritis Treatment Market is enhanced by medicine precision, providing fresh possibilities in the psoriatic arthritis treatment field through the customization of therapies to the genetic, biomarker, and lifestyle parameters of an individual. By enabling physicians to forecast patient response to candidate biologics or small-molecule therapeutics, this approach will eliminate trial-and-error prescribing and decrease overall treatment failure through a drug-tailored approach. It is estimated that nearly 70% of patients with chronic disorders can find their precision treatment method helpful, which is why it can effectively be applied in arthritis care. Precision medicine complications are reduced by matching therapy to the specific inflammatory pathways that cause a patient to develop psoriatic arthritis, thereby boosting patient compliance in the long term. It also facilitates the detection of symptoms of drug resistance early to make appropriate changes in the treatment so that the disease can be easily controlled.

The incorporation of sophisticated diagnostics, including molecular profiling and biomarker testing, is making them increasingly used in clinical practice. This enhances not only patient-specific care but also means that the available healthcare resources get used more effectively by not wasting resources on unnecessary treatments. Pharmaceuticals are spending big on developing the next-generation biologics and inhibitors assumed to suit these precision models. This progress promotes improved disease management and a general improvement in the patients' lives. Eventually, precision medicine is transforming the therapeutic outcomes and innovation in the global psoriatic arthritis treatment market.

What are the key market segments in the Psoriatic Arthritis Treatment industry?

Based on the molecule type, the Psoriatic Arthritis Treatment Market is classified into monoclonal antibodies, fusion proteins, small molecules, biosimilars, and conventional synthetic drugs (csDMARDs), which attain a large share because of their high efficacy and wide application in the domains of TNF, IL-17, and IL-23 inhibitors. Etanercept and other types of proteins, such as fusion proteins, provide valuable immune modulation. The small molecule market, especially those used in JAK inhibitors and PDE4 inhibitors such as apremilast, is growing fast due to the oral convenience and favorable safety.

In TNF inhibitors, biosimilars are experiencing robust sales, as they are more cost-effective and are enabling more patients to be reached in emerging economies. The traditional synthetic DMARDs (csDMARDs), such as methotrexate, continue to be prevalent to considered as first-line therapy but are becoming increasingly substituted or supplemented with the biologics in moderate-to-severe disease. The fact that there is a trend that shifts toward more effective and precise treatment is evidenced by the transition to next-generation agents, which target molecules instead of traditional agents. In general, the two fastest-growing segments are monoclonal antibodies and small molecules in the forecast period.

Based on the mechanism of action, the Psoriatic Arthritis Treatment Market is classified into TNF-α Inhibitors, IL-17 Inhibitors, IL-12/23 Inhibitors, IL-23 Inhibitors, JAK Inhibitors, PDE4 Inhibitors, Conventional DMARDs, and NSAIDs & Corticosteroids. The psoriatic arthritis treatment market by mechanism of action is dominated by TNF-alpha inhibitors, which remain the oldest family with established long-term efficacy. Nevertheless, IL-17 inhibitors are quickly amassing a market share with better results on joint and skin symptoms and are an increasingly favored therapy in most treatment guidelines.

IL-12/23 and IL-23 inhibitors are also gaining popularity, especially in the management of patients with psoriasis and psoriatic arthritis, because of their added advantage. JAK inhibitors continue to experience robust adoption as pill-based options that are favorable among patients in need to avoid needle-based treatment. Weaker PDE4 inhibitors are of significance in the mild-to-moderate cases where biologics are not necessary. When initial treatment is provided with conventional DMARDs, these agents are increasingly combined with targeted agents to provide better control of the disease. In general, the market is trending towards the replacement of broad immunosuppressants with area-specific targeted drugs to provide innovation and redefine treatment algorithms.

Which regions are leading the Psoriatic Arthritis Treatment market, and why?

The North America Psoriatic Arthritis Treatment Market is leading due to a high prevalence rate of psoriatic arthritis, a high proportion of advanced biologics, and good healthcare infrastructure. The United States makes its own mark in the local market because of favorable reimbursement policies, high biologic penetration, and supervision of pharmaceutical companies of stature like AbbVie, Amgen, Novartis, and Janssen. The increased demand for IL-17 and IL-23 inhibitors and the widening offloading of JAK inhibitors are changing the therapy map. The region also leads in the adoption of biosimilars, especially in the area of TNF inhibitors, due to cost control measures.

The growing interest in treatment according to target, patient awareness and insight, and early detection initiatives also contribute to demand. Research and development, along with clinical trials in next-generation immunotherapies, are gaining pace. The growth of the Canadian market is also stable due to governmental healthcare initiatives and biosimilar-conducive policies. Overall, North America will remain the leader among the countries, enjoying early adoption of technology and high affordability of treatments.

The Asia Pacific Psoriatic Arthritis Treatment Market is growing due to the high awareness rate, higher access to healthcare, and improved diagnosis of the disease in China, India, and Japan. The increased use of biologics and targeted synthetic DMARDs, with the help of expanding healthcare infrastructure, is driving their demand. The introduction of relatively inexpensive biosimilars is considerably raising the affordability of treatments in cost-sensitive markets. Japan is in the lead in adopting advanced therapy because the country possesses great reimbursement systems and designated filing approvals at the early stages.

China is also experiencing a high level of uptake owing to local development and government health programs. India and the Southeast Asian countries are recording growth through enhancing access to generics and biosimilars. The increasing levels of autoimmune diseases, the issue of urbanization, and changes in lifestyles are further adding to the pool of patients. Accessibility is being boosted by solid investments by the multinational and domestic pharma players in market expansion and clinical trials. In general, the market of Asia-Pacific is driven by cost-competitiveness, the growing number of patients, and the high rate of adoption of new therapies.

What does the competitive landscape of the Psoriatic Arthritis Treatment market look like?

The Global Psoriatic Arthritis Treatment Market is moderately consolidated and highly competitive, with major players having entrenched portfolios in the pharmaceutical industry. AbbVie remains dominant because it has managed to implement a smooth shift to its next-generation immunology blockbusters Skyrizi and Rinvoq, whereas Johnson & Johnson is gearing up Stelara and the extension of Tremfya indications to achieve broader coverage of patient populations. Pfizer and Bristol Myers Squibb are increasingly competitive as they are improving by enhancing oral small molecules, especially JAK and TYK2 inhibitors, to provide patients greater convenience and performance. Bimekizumab, which is a novel IL-17 pathway agent, has already gained great momentum with UCB introducing it to diversify the treatment options. In the meantime, players in the biosimilar sphere, including Samsung Bioepis, Biocon, Alvotech, and Celltrion, are redefining pricing dynamics by offering alternatives to existing biologics, i.e., TNF inhibitors and ustekinumab, at lower prices.

The shift of the market to a new generation of targeted drugs is observed, and at the same time, the affordability and availability of the treatment are increased by biosimilars. Firms are also achieving competitiveness through the investment in digital health tools, real-world data, and patient-support programs to increase adherence and outcomes. Strategic partnerships with companies and the licensing system, and expansion to new regions are emerging as the key tools to maintain and increase the market share around the globe. The deal underlicensed by Bio-Thera Solutions and STADA Arzneimittel concerns the arthritis biosimilar BAT1806, to commercialize the product in various sectors in Europe and other parts of the world. These collaborations are not only able to increase global presence but also illustrate the growing significance of biosimilars in solving the problem of affordability.

Psoriatic Arthritis Treatment Market, Company Shares Analysis, 2024

To explore in-depth analysis in this report - Request Sample Report

Which recent mergers, acquisitions, or product launches are shaping the Psoriatic Arthritis Treatment industry?

• In June 2025, the European Commission granted marketing authorization for Qoyvolma® (Celltrion), an ustekinumab biosimilar, for treating plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis. This approval followed a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) in March 2025, and it is Celltrion's second ustekinumab biosimilar to receive EU approval.
• In May 2025, Sandoz launched the Pyzchiva® autoinjector across Europe, offering the first autoinjector delivery option for ustekinumab biosimilars, enhancing patient self-administration comfort and convenience.
• In February 2025, Sandoz (via Samsung Bioepis) launched the Pyzchiva biosimilar (ustekinumab-ttwe), a substitute for Stelara, in the U.S. for conditions including psoriatic arthritis; it offers multiple dosage forms, including pre-filled syringes and IV vials.

Report Coverage:

By Molecule Type

• Monoclonal Antibodies
• Fusion Proteins
• Small Molecules Biosimilars
• Conventional Synthetic Drugs (csDMARDs)

By Mechanism of Action

• TNF-α Inhibitors
• IL-17 Inhibitors
• IL-12/23 Inhibitor
• IL-23 Inhibitors
• JAK Inhibitors
• PDE4 Inhibitor
• Conventional DMARDs
• NSAIDs & Corticosteroids

By Route of Administration

• Subcutaneous (SC) injection
• Intravenous (IV) infusion
• Oral
• Intra-articular

By Phenotype

• Peripheral arthritis-predominant
• Axial PsA
• Enthesitis-dominant
• Dactylitis-dominant
• Nail disease involvement
• Psoriasis with joint involvement

By End-user

• Hospitals & Hospital Pharmacies
• Specialty Clinics
• Ambulatory Infusion Centers
• Self-administration settings
• Retail & Online Pharmacies
• Other

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• AbbVie Inc.
• Johnson & Johnson Services, Inc.
• Novartis International AG
• Eli Lilly and Company
• Amgen Inc.
• Pfizer Inc.
• UCB S.A.
• Bristol Myers Squibb Company
• GlaxoSmithKline plc
• Biogen Inc.
• Gilead Sciences, Inc.
• Sun Pharmaceutical Industries Ltd.
• AstraZeneca plc
• Takeda Pharmaceutical Company Limited
• Enlivex Therapeutics Ltd.

Frequently Asked Questions (FAQs)